> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-230/
- Published: 2019-07-07T12:00:00.000Z
- Updated: 2026-09-15T01:35:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144472

[**Guide on Epidermolysis Bullosa Drug Development**](http://fdaweb.com/login.php?sa=v&aid=D5144460&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA makes available a final guidance entitled “Epidermolysis Bullosa (EB): Developing Drugs for Treatment of Cutaneous Manifestations.” 07/08/2019

[**Final Rule on CDRH Supervisory Review of Decisions**](http://fdaweb.com/login.php?sa=v&aid=D5144464&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA issues a final rule to amend its regulations on internal agency supervisory review of certain decisions related to devices regulated by CDRH. 07/08/2019

[**Device GMP Advisory Committee Seeks Reps**](http://fdaweb.com/login.php?sa=v&aid=D5144465&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA requests that any industry organizations interested in participating in the selection of a nonvoting industry representative to serve on CDRH’s Device Good Manufacturing Practice Advisory Committee notify it in writing. 07/08/2019

[**Patient Engagement Panel to Review Device Cybersecurity**](http://fdaweb.com/login.php?sa=v&aid=D5144469&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA announces a 9/10 Patient Engagement Advisory Committee meeting to discuss and make recommendations on “Cybersecurity in Medical Devices: Communication That Empowers Patients.” 07/08/2019

[**Comment Period Reopened on Drug Supply Chain**](http://fdaweb.com/login.php?sa=v&aid=D5144468&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA reopens the comment period for the notices that published in the Federal Register of 4/15 and 4/28 regarding issues related to the drug supply chain. 07/08/2019

[**Docket Number Corrected on REMS Guidance**](http://fdaweb.com/login.php?sa=v&aid=D5144470&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA corrects a 9/5/2017 notice entitled “Providing Regulatory Submissions in Electronic Format — Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling; Draft Guidance for Industry.” 07/08/2019

[**Claforan Not Withdrawn Due to Safety/Efficacy: FDA**](http://fdaweb.com/login.php?sa=v&aid=D5144471&cate=FR&stid=%241%24R62.Gm0.%24S5j9aaIUpLS5SQ3jU1rPp%2F&ref=fdaweb.com)  
*Federal Register* notice: FDA determines that U.S. Pharmaceutical Holdings’ Claforan (cefotaxime sodium) for injection was not withdrawn from sale for reasons of safety or effectiveness. 07/08/2019

[**Workshop on Heart Failure Drug Endpoints**](https://www.fdaweb.com/workshop-on-heart-failure-drug-endpoints/)  
*Federal Register* notice: FDA announces a 7/26 public workshop entitled “Endpoints for Drug Development in Heart Failure.” 06/28/2019  
  
[**Draft Guide on Heart Failure Drug Endpoints**](https://www.fdaweb.com/draft-guide-on-heart-failure-drug-endpoints/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Treatment for Heart Failure: Endpoints for Drug Development.” 06/28/2019

[**Proposed Rule on Biologic Master Files**](https://www.fdaweb.com/proposed-rule-on-biologic-master-files/)  
*Federal Register* proposed rule: FDA proposes to amend its regulations concerning the use of master files for biological products. 06/28/2019